BioCardia Q2 FY26 net loss narrows to $1.61 million; cash rises to $4.12 million as of June 30, 2026
BCDA•Quarterly results narrow loss
BioCardia posted a net loss of $1.61 million in Q2 2026, narrowing from $2.05 million a year earlier.
Loss per share improved to $0.13 from $0.40 in the prior-year quarter.
Cash position and financing activity
Cash and cash equivalents ended the quarter at $4.12 million. Net proceeds of about $4.9 million were raised via an at-the-market facility.
Regulatory update on CardiAMP and Helix
Management cited PMDA support for a Q4 Shonin submission for CardiAMP, FDA feedback that CardiAMP HF II may support PMA, and potential De Novo Helix approval.
Expenses fall as trial closeout reduces R&D spending
Research and development expense fell to $893,000 from $1.37 million, due to closeout of the CardiAMP HF trial.
